Key result
Beta-adrenergic blocking agents conclusively reduce the chances of recurrent infarction and death in survivors of myocardial infarction.
Why the study?
Do beta-Adrenergic blocking agents reduce recurrent infarction and death in survivors of myocardial infarction?
Do beta-Adrenergic blocking agents reduce recurrent infarction and death in survivors of myocardial infarction?
This review highlights the conclusive evidence that beta-blockers reduce recurrent infarction and mortality in post-myocardial infarction patients.
Supports beta-blocker use post-MI; confirms prior evidence but leaves open need for modern validation.
Survivors of myocardial infarction who have been discharged from the hospital face an increasing cumulative risk of suffering another infarction or death. beta-Adrenergic blocking agents have undergone various trials to reduce these risks and prolong life. Although earlier trials have shown conflicting results, recent studies have conclusively demonstrated the beneficial role of this class of drugs in reducing the chances of recurrent infarction and death. These studies are briefly reviewed and appropriate conclusions as well as recommendations are made.
No takes yet. Share an insight, caveat, or question.
Abdul Hakim Khan (1983) conducted a review in Myocardial infarction. beta-Adrenergic blocking agents was evaluated on Recurrent infarction and death. Beta-adrenergic blocking agents conclusively reduce the chances of recurrent infarction and death in survivors of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: